Clinical Trial Update: Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating the combination of an anti-CTLA-4 antibody with Sintilimab and chemotherapy for resectable stage II-III non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-CTLA-4 antibody
• Chemotherapy (neoadjuvant)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC Stage II, NSCLC Stage III | Phase 2 | Status: RECRUITING